Natera, Inc. (NASDAQ: NTRA), a pioneer in cell-free DNA testing and precision medicine, has announced that Medicare will now cover its Signatera MRD (molecular residual disease) assay for a wider range of cancers. The decision, effective under LCD L38779, includes Medicare beneficiaries with colorectal, breast, bladder, ovarian, and lung cancers, as well as patients undergoing pan-cancer immunotherapy monitoring.
This expanded coverage follows the presentation of a pan-cancer study involving 392 patients at the recent 2025 American Society of Clinical Oncology (ASCO) Annual Meeting earlier this week. The study highlighted the clinical utility of the Signatera Genome assay, which utilizes Natera’s proprietary multiplex PCR-NGS technology for deep sequencing of targeted high-quality variants.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.